COXFA4L2 and cancer: Besides, Yun L et al.found that NDUFA4L2 was significantly enriched in the mitochondria under hypoxic conditions and was associated with cancer progression and poor prognosis in human CRC patients [31] (In other diseases, during inflammation, a cytokine modulator of cytochrome C oxidase (MOCCI), a para homolog of NDUFA4, replaces NDUFA4 during inflammation to reduce mitochondrial membrane potential and reduce ROS production, leading to cell protection and the suppression of the immune response [55]).